Experimental pill promises new hope for deadly pancreatic cancer

Experimental Pill Promises New Hope for Deadly Pancreatic Cancer

New treatment shows promise in extending survival and improving quality of life for patients with advanced stages

Experimental pill promises new hope for deadly - Researchers in WASHINGTON have unveiled a groundbreaking development in the fight against pancreatic cancer, reporting that a novel pill significantly prolonged the lives of patients with advanced stages of the disease. The findings, presented at the American Society for Clinical Oncology meeting in Chicago, suggest this experimental therapy could herald a major breakthrough for a condition long regarded as one of the most lethal cancers.

The drug, named daraxonrasib, targets a mutated protein central to tumor progression in over 90% of pancreatic cancer cases. This protein, part of the RAS gene family, has been a stubborn challenge for scientists, as its structure made it difficult for traditional drugs to effectively bind to it. For decades, this genetic driver—specifically KRAS mutations—has been considered “undruggable,” limiting treatment options for patients. Daraxonrasib, however, employs a molecular glue to adhere to multiple KRAS subtypes, effectively disrupting their role in cancer growth.

“Having treated pancreatic cancer for 16 years, I actually started crying” when first seeing the study results, Dr. Rachna Shroff of the University of Arizona Cancer Center said from the ASCO meeting. She noted how the treatment provided “durable and meaningful benefit” to patients, who remained on it longer than those receiving chemotherapy.

The clinical trial involved 500 individuals with metastatic cancer that had resisted prior therapies. Patients were randomly assigned either the experimental pill or standard chemotherapy. The results showed that those taking daraxonrasib lived for a median of 13.2 months, compared to 6.7 months for chemotherapy recipients. While the difference may appear modest, Dr. Zev Wainberg of the University of California, Los Angeles, highlighted its significance as the first drug to demonstrate a marked advantage over existing treatments.

“This is a very large step forward,” Wainberg said, emphasizing that the pill does not cure the disease but offers a substantial improvement in survival outcomes. The drug’s impact was notable not only in extending life but also in reducing severe side effects, allowing patients to maintain a better quality of life. Many still used the medication after data analysis, suggesting the survival gap may grow as researchers continue monitoring long-term effects.

Dr. Brian Wolpin of the Dana-Farber Cancer Institute described the pill as a “new standard of care” for patients with previously treated metastatic pancreatic cancer. He also noted that further studies will explore its potential in earlier stages of the disease, including whether tumor shrinkage could enable more patients to undergo surgery. “This could transform how we approach treatment,” Wolpin added.

Despite the drug’s efficacy, some side effects—like rash and mouth sores—may affect patient adherence. However, these are generally less severe than those associated with traditional chemotherapy. The study’s funding came from Revolution Medicines, and the Food and Drug Administration is accelerating its review process. Meanwhile, the agency has authorized an “expanded access” program, allowing patients meeting specific criteria to try the drug before it receives full approval.

The drug’s potential was highlighted by former U.S. Senator Ben Sasse, who shared his experience on “60 Minutes” about how it reduced his pain. This personal account has spurred oncologists to seek out the treatment for eligible patients, creating a surge in interest and demand. “It’s changed the conversation,” said Dr. Andrew Coveler of the Fred Hutchinson Cancer Center, who was not involved in the research.

Revolution Medicines’ drug represents a shift in how pancreatic cancer is treated. Unlike other cancers that have benefited from a range of chemotherapy alternatives, pancreatic cancer has remained a particularly difficult challenge due to its aggressive nature and resistance to conventional therapies. The American Cancer Society estimates that approximately 67,000 new cases will be diagnosed in the U.S. this year, with over 52,000 deaths expected. The five-year overall survival rate for pancreatic cancer is just 13%, underscoring the urgency for better options.

The study’s success has sparked optimism among oncologists. Dr. Shroff noted that the treatment’s ability to sustain benefits over time is a major breakthrough. “Patients stayed on this therapy because it was effective,” she explained. Other researchers have also expressed cautious hope, with dozens of experimental drugs currently in development. These include vaccines designed to prevent cancer recurrence after surgery by training the immune system to recognize mutated proteins.

Wainberg and his team plan to investigate whether daraxonrasib performs better against specific KRAS subtypes. If so, it could lead to more personalized treatment strategies. “This thing works drastically differently,” Coveler said, emphasizing the drug’s unique mechanism. The findings suggest that targeting RAS mutations directly may be a game-changer in a field that has long struggled to make progress.

As the drug moves closer to approval, its impact on patient care is becoming increasingly evident. For those with advanced pancreatic cancer, the pill offers a glimmer of hope—a chance to live longer and with more comfort. With the FDA’s expedited review and expanded access program, more patients may soon benefit from this innovation, potentially altering the trajectory of treatment for a disease that has so often proven intractable.